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P
ulmonary hypertension (PH) is a condition with high 
morbidity and mortality. Regardless of cause, PH has a 
negative efect on quality of life (1) and is life-shortening, 
even with modern treatment strategies. Right-sided heart 
catheterization (RHC) is the reference standard for PH, 
which is deined as a mean pulmonary arterial pressure 
(mPAP) of at least 25 mm Hg at rest (2).
RHC is an invasive test with a serious complication 
rate of 1% (3), so current guidelines recommend echo-
cardiography to classify patients suspected of having PH 
as having low, medium, or high risk of PH (2). Doppler 
echocardiographic measurement of systolic pulmonary 
arterial pressure requires an estimation of right atrial 
pressure; the current estimation from inferior vena cava 
size does not enable an accurate prediction of the true 
right atrial pressure at RHC (4). Echocardiography also 
requires tricuspid regurgitation, which, while commonly 
seen in PH, is not always present, and severe tricuspid 
regurgitation causes erroneous low or high echocardio-
graphic predictions of mPAP (5). As such, estimation 
of pulmonary arterial pressures from echocardiography 
shows only moderate agreement with that measured with 
RHC (6), with 95% limits of agreement at Bland-Alt-
man analysis ranging from +38.8 to 240.0 mm Hg (7). 
A large meta-analysis showed only modest diagnostic ac-
curacy of echocardiography for the presence of PH, with 
a sensitivity of 83% and a speciicity of 72% (8). Further-
more, echocardiography is not possible in the context of 
severe lung disease owing to the loss of acoustic windows, 
and when it is measurable it is often erroneous (9).
A number of cardiac MRI metrics have been proposed 
as predictors of increased pulmonary arterial pressure, 
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Purpose: To derive and test multiparametric cardiac MRI models for the diagnosis of pulmonary hypertension (PH).
Materials and Methods: Images and patient data from consecutive patients suspected of having PH who underwent cardiac MRI and 
right-sided heart catheterization (RHC) between 2012 and 2016 were retrospectively reviewed. Of 2437 MR images identiied, 
603 it the inclusion criteria. he mean patient age was 61 years (range, 18–88 years; mean age of women, 60 years [range, 18–84 
years]; mean age of men, 62 years [range, 22–88 years]). In the irst 300 patients (derivation cohort), cardiac MRI metrics that 
showed correlation with mean pulmonary arterial pressure (mPAP) were used to create a regression algorithm. he performance of 
the model was assessed in the 303-patient validation cohort by using receiver operating characteristic (ROC) and x2 analysis.
Results: In the derivation cohort, cardiac MRI mPAP model 1 (right ventricle and black blood) was deined as follows: 2179 + 
log
e
 interventricular septal angle 3 42.7 + log
10
 ventricular mass index (right ventricular mass/left ventricular mass) 3 7.57 + black 
blood slow low score 3 3.39. In the validation cohort, cardiac MRI mPAP model 1 had strong agreement with RHC-measured 
mPAP, an intraclass coeicient of 0.78, and high diagnostic accuracy (area under the ROC curve = 0.95; 95% conidence interval 
[CI]: 0.93, 0.98). he threshold of at least 25 mm Hg had a sensitivity of 93% (95% CI: 89%, 96%), speciicity of 79% (95% CI: 
65%, 89%), positive predictive value of 96% (95% CI: 93%, 98%), and negative predictive value of 67% (95% CI: 53%, 78%) in 
the validation cohort. A second model, cardiac MRI mPAP model 2 (right ventricle pulmonary artery), which excludes the black 
blood low score, had equivalent diagnostic accuracy (ROC diference: P = .24).
Conclusion: Multiparametric cardiac MRI models have high diagnostic accuracy in patients suspected of having pulmonary 
hypertension.
Published under a CC BY 4.0 license.
Online supplemental material is available for this article.
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Image Acquisition
Cardiac MRI was performed with a 1.5-T whole-body im-
ager (HDx; GE Healthcare, Milwaukee, Wis), with the pa-
tient supine, by using an eight-channel cardiac coil. Stan-
dard four-chamber and short-axis balanced steady-state free 
precession cine stack images were acquired from base to 
apex. Phase contrast imaging was performed orthogonal to 
the main pulmonary artery. Black blood imaging of the pul-
monary arteries was performed by using a double inversion 
recovery fast spin-echo sequence, acquiring images with 
8-mm-thick sections through the main and branch pulmo-
nary arteries (12). he sequence parameters are provided in 
Appendix E1 (online).
Image Analysis
MR images were manually analyzed by D.A.C. (an MRI ra-
diographer with 9 years of cardiac experience) with use of 
an Advantage workstation (version 4.4, GE Healthcare) 
with ReportCard software (GE Healthcare). Analysis was 
performed prospectively and sequentially at the time of 
imaging, with remote supervision by A.J.S. (a consultant 
cardiac radiologist with 12 years of experience) when re-
quired. Image analysis was performed before RHC and 
while blinded to all other clinical details. he results of the 
analysis and, frequently, the contours were reviewed at the 
weekly multidisciplinary meeting, and any studies that were 
not of diagnostic quality were excluded. All cardiac MRI 
metrics outlined below were remeasured in 15 randomly 
selected studies from the validation cohort by a second re-
viewer (C.S.J., a general radiologist with 6 years of experi-
ence) who was blinded to the indings of the previous analy-
sis and to all clinical data.
Left and right ventricular end-diastolic volume, end-
systolic volumes, and right and left ventricular stroke 
volume and mass were calculated (indexed to body sur-
face area) and right and left ventricular ejection fraction, 
ventricular mass index (right ventricular mass divided by 
left ventricular mass) (13,14), and interventricular sep-
tal angle were measured as previously described (15–17). 
Maximal and minimal pulmonary artery areas were manu-
ally traced, and relative area change was deined as follows: 
pulmonary artery relative area change = (maximum area 2 
minimum area)/minimum area (18,19). Pulmonary artery 
average velocity was calculated by using the phase contrast 
low as forward pulmonary artery velocity/diastolic pulmo-
nary artery size (Fig 2). he reproducibility of these cardiac 
MRI metrics between the reviewer D.A.C. (MR radiogra-
pher) and A.J.S. (consultant cardiac radiologist) has been 
previously published in a cohort of patients with pulmonary 
arterial hypertension (group 1) (20).
Black blood slow low was visually scored by A.J.S. by using a 
semiquantitative scale from 0 to 5 depending on how proximal 
the low feature is seen in the pulmonary arterial tree (Fig 3), 
as follows: 0 = absent, 1 = segmental, 2 = lobar, 3 = distal main, 
4 = proximal main, and 5 = trunk. his scale has been shown 
to have good interobserver reproducibility (21).
Abbreviations
CI = conidence interval, mPAP = mean pulmonary arterial pressure, 
PH = pulmonary hypertension, RHC = right-sided heart catheteriza-
tion, ROC = receiver operating characteristic
Summary
A cardiac MRI diagnostic model for the identiication of pulmonary 
hypertension, incorporating measurements from the right ventricle 
and pulmonary artery, accurately correlates with right-sided heart 
catheterization–measured mean pulmonary arterial pressure and 
represents a noninvasive method to assess the diagnosis of pulmonary 
hypertension.
Implications for Patient Care
 n he mean pulmonary arterial pressure determined with a cardiac 
MRI model that includes the angle of the interventricular septum, 
ventricular mass index, and the extent of black blood slow low 
correlated with that measured with right-sided heart catheteriza-
tion.
 n Cardiac MRI parameters can help identify patients with high sen-
sitivity (93%) and moderate speciicity (79%).
and a number of image-based models (physiologic, empirical, 
and computational) have been proposed. Black blood scoring 
has been shown to be a useful diagnostic marker in PH; how-
ever, it is not widely adopted in MRI protocols. hus, develop-
ing models with and without this parameter would be advanta-
geous. Previously identiied cardiac MRI metrics and markers 
have been tested in relatively small numbers and often have 
modest diagnostic accuracy.
We hypothesized that (a) cardiac MRI parameters from 
both the heart and pulmonary arteries have additive diagnos-
tic value in patients suspected of having PH and (b) a cardiac 
MRI multiparametric model could help diagnose PH with 
high accuracy.
he aim of this study was to derive two regression models, 
one with and one without black blood scoring, to diagnose PH 
with use of cardiac and pulmonary vascular cardiac MRI.
Materials and Methods
Patients
Consecutive incident patients suspected of having PH who 
were referred to a tertiary PH center from April 2012 to 
October 2016 were identiied from the ASPIRE database 
(Assessing the Spectrum of Pulmonary Hypertension Identi-
ied at a Referral Center) (10). Patients were separated by date of 
imaging into a derivation (n = 300) and a validation (n = 303) 
cohort. Only incident patients who underwent cardiac MRI 
and RHC within 14 days were included. Any patient with a 
left atrial volume index of 41 mL or higher at cardiac MRI was 
excluded as this is a potential marker of PH due to left-sided 
heart disease (11). Figure 1 shows the process of patient selec-
tion. Treatment was always initiated after RHC and cardiac 
MRI had been performed. Ethical approval was granted from 
a local ethics committee for this retrospective study, and the 
requirement to obtain informed written consent was waived 
(ref c06/Q2308/8).
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thresholds, one that was highly speciic and one 
that had a balance of speciicity and sensitivity 
(the Youden index). A second regression equa-
tion was calculated without the use of black 
blood slow low, and diagnostic accuracy was cal-
culated with the same method.
Validation cohort.—he second half of the patients 
(n = 303) was used for validation. he correlation 
of the derived regression equations for PH diagno-
sis against RHC-measured mPAP was calculated. 
he accuracy of these models was assessed with 
Bland-Altman analysis, and the intraclass correla-
tion coeicient was calculated between the model- 
and RHC-measured mPAP (two-way mixed efects 
model, absolute agreement deinition, and single 
measures). heir diagnostic performance was as-
sessed by using ROC curve analysis, sensitivity, 
speciicity, negative and positive predictive values, 
and negative and positive likelihood ratios. For 
comparison of ROC curves, we used a nonpara-
metric method that is analogous to the Wilcoxon–
Mann-Whitney test. Reproducibility between 
D.A.C. and C.S.J. was analyzed with the intraclass 
correlation coeicient by using a two-way mixed ef-
fects model and average measures.
Results
Patients
he ASPIRE MRI subregistry contains 2437 cardiac MR 
images, and within this there are 1272 incident images with 
suspected PH. Of the patients with incident images, 957 
underwent RHC and cardiac MRI within 14 days. Of those 
957 patients, 603 had a left atrial volume index of less than 
41 mL. he irst 300 patients were used as the derivation 
cohort and the second 303 as the validation cohort (Figure 
1). Baseline characteristics of the patients are provided in 
Table 1. Apart from cardiac index, there were no signiicant 
diferences in the clinical demographics of patients between 
derivation and validation cohorts (Table 2). he diference 
in cardiac index between the two groups was very small 
and unlikely to be of clinical signiicance, as outlined in 
Table 1. Fifty-two patients in the derivation cohort and 45 
in the validation cohort did not have PH. In total, there 
were 97 patients who did not have PH, 264 patients with 
pulmonary arterial hypertension, 11 with PH due to left-
sided heart disease (even after exclusion of dilated left atria), 
60 with PH due to respiratory disease, 157 with chronic 
thromboembolic disease, and 18 with PH due to unclear or 
multifactorial mechanisms. hree hundred ifteen patients 
were excluded because MRI was performed more than 14 
days from RHC. his excluded group consisted of 37 pa-
tients without PH, 154 patients with group 1 pulmonary 
arterial hypertension, 19 with PH due to left-sided heart 
disease, 16 with PH due to lung disease, 81 with chronic 
thromboembolic PH, and eight with unclear causes.
Right-sided Heart Catheterization
RHC was performed as part of the routine clinical pathway 
by the PH clinicians (D.G.K., C.E., and R.C.), all with more 
than 10 years of experience, by using a balloon-tip 7.5-F ther-
modilution catheter (Becton-Dickinson, Franklin Lakes, NJ). 
PH was deined as a resting mPAP of 25 mm Hg or higher (2).
Statistical Analysis
Statistical analysis was performed with software (SPSS 22; IBM, 
Chicago, Ill), and graphs were produced by using GraphPad 
Prism (GraphPad Software, La Jolla, Calif ). Unless otherwise 
stated, P , .05 was considered indicative of a statistically sig-
niicant diference. Comparison of continuous variables between 
groups was made by using the Student t test and the x2 test for 
discrete variables.
Derivation cohort.—he irst 300 patients were used as a 
derivation cohort to derive diagnostic PH models. he Pear-
son correlation coeicients between quantiiable cardiac MRI 
characteristics and mPAP were calculated. As multiple cor-
relations were assessed, the risk of type 1 error was reduced 
by using Bonferroni correction, so P , .002 was considered 
indicative of a statistically signiicant diference (30 diferent 
correlations). Scatterplots were constructed to ensure linear-
ity between cardiac MRI metrics and mPAP. Any signiicant 
correlations were used to calculate a linear regression equa-
tion for estimation of mPAP. A receiver operating characteris-
tic (ROC) curve was constructed to assess suitable diagnostic 
Figure 1: Patient flowchart.
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data). Visual inspection of the scatterplots of interventricular 
septal angle and ventricular mass index revealed an exponential 
relationship, so the log
10
 of the ventricular mass index and log
e
 
of septal angle were used in further calculations.
Regression analysis, performed in a forward direction for any 
metric that showed a correlation with mPAP (P , .2), produced 
the following equation: cardiac MRI mPAP model 1 (right ven-
tricle and black blood) = 2179 + log
e
 interventricular septal angle 
3 42.7 + log
10
 ventricular mass index (right ventricular mass/left 
ventricular mass) 3 7.57 + black blood slow low score 3 3.39.
A threshold of at least 25 mm Hg was identiied as having an 
optimal diagnostic threshold (Youden index), with a sensitivity 
of 96% and a speciicity of 73%.
Derivation Cohort
he strongest correlations with mPAP were for systolic inter-
ventricular septal angle, black blood score, right ventricular 
ejection fraction, right ventricular end-systolic volume index, 
and ventricular mass index (R = 0.74, 95% conidence interval 
[CI]: 0.69, 0.79; R = 0.69, 95% CI: 0.63, 0.75; R = 20.60, 
95% CI: 20.53, 0.67; R = 0.59, 95% CI: 0.51, 0.65; and R = 
0.53, 95% CI: 0.44, 0.61, respectively). Higher right ventricu-
lar volumes (end-diastolic and end-systolic volumes), lower left 
atrial volume index and left ventricular end diastolic volume, 
larger pulmonary artery size, and lower pulmonary arterial rel-
ative area change and velocity all showed statistically signiicant 
correlation with higher mPAP (see Table E1 [online] for the 
Figure 3: Semiquantitative scoring of black blood slow flow score. The score is based on how proximal signal can be seen in pulmonary arter-
ies, where 0 = no slow flow, 1 = signal within segmental pulmonary arteries, 2 = signal within lobar branches, 3 = signal within distal main pul-
monary artery, 4 = signal within proximal main pulmonary artery, and 5 = signal within proximal main pulmonary artery. Diagram demonstrates 
different parts of pulmonary artery and naming convention. Example images of each score are provided with their mean pulmonary artery pres-
sure (mPAP) as a reference.
Figure 2: Representative steady-state free precession short-axis cine images of pulmonary artery demonstrate calculation of the quantitative 
metrics pulmonary arterial relative area (left), with systolic pulmonary artery size shown as solid line and diastolic pulmonary artery size shown as 
dotted line, ventricular mass index (middle), with right ventricular mass shown as dotted area and left ventricular mass shown as solid lined area, 
and interventricular septal angle (right), shown by solid line. LV = left ventricle, RV = right ventricle.
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+ diastolic pulmonary artery area 
3 0.009. For cardiac MRI mPAP 
model 2, the threshold of at least 
25 mm Hg was again identiied 
as having an optimal diagnostic 
threshold.
Validation Cohort
Agreement.—Cardiac MRI 
mPAP model 1 correlated strongly 
with RHC-measured mPAP (R 
= 0.80; 95% CI: 0.75, 0.84). 
Bland-Altman analysis showed a 
small bias (3.9%), with reasonable 
95% agreement (242% to 50%) 
and an excellent intraclass correlation coeicient for the esti-
mation of mPAP of 0.78 (95% CI 0.73, 0.83). he cardiac 
MRI mPAP model 2 also strongly correlated with mPAP (R = 
0.80; 95%: CI: 0.76, 0.85), with a small bias (0.9%) and again 
reasonable 95% agreement (243% to 46%), with an intraclass 
After exclusion of black blood slow low, the following re-
gression equation was derived: cardiac MRI mPAP model 2 
(right ventricle pulmonary artery) = 2231.423 + log
e
 in-
terventricular septal angle 3 53.8 + log
10
 ventricular mass 
index (right ventricular mass/left ventricular mass) 3 8.708 
Table 1: Baseline Demographics for All Patients according to PH Status and Derivation or Validation Cohort
Parameter No PH (n = 97) PH (n = 506) P Value
Derivation Cohort  
(n = 300)*
Validation Cohort  
(n = 303)† P Value
Age (y) 56 6 16 52 6 13 ,.001 60 6 14 61 6 14 .28
Sex‡ .10 .24
 F 66 299 189 176
 M 31 207 111 127
WHO functional class‡ ,.001 .08
 I 0 1 0 1
 II 35 29 34 30
 III 50 409 223 236
 IV 3 60 33 30
ISWT (m) 308 6 223 211 6 182 ,.001 228 6 184 223 6 198 .78
mPAP (mm Hg) 19 6 3 47 6 13 ,.001 42 6 16 42 6 15 .94
mRAP (mm Hg) 5.7 6 2.9 11 6 6 ,.001 10 6 6 10 6 6 .32
PAWP (mm Hg) 10 6 4 11 6 4 .01 11 6 4 11 6 4 .22
Cardiac index (L/min/m2) 3.1 6 0.76 2.5 6 0.76 ,.001 2.8 6 0.8 2.5 6 0.8 ,.001
PVRI (dyne · sec · m2/cm5) 74 6 41 390 6 253 ,.001 326 6 241 345 6 277 .38
SvO
2
 (%) 71 6 7 63 6 9 ,.001 64 6 9 64 6 9 .93
FEV1 (% predicted) 74 6 11 68 6 13 ,.001 78 6 24 78 6 25 .89
FVC (% predicted) 84 6 19 80 6 25 .25 82 6 23 80 6 24 .86
FEV1/FVC 74 6 12 68 6 13 ,.001 68 6 13 70 6 12 .24
TLCO (% predicted) 62 6 18 43 6 22 ,.001 46 6 23 46 6 21 .98
Time between RHC and MRI (d) 1 6 2 1 6 2 .65 1 6 2 1 6 2 .59
Note.—Except where indicated, data are means 6 standard deviations. P values were calculated by using the Student t test for continuous 
variables and the x2 test for discrete variables. FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, ISWT = incre-
mental shuttle walk test, mPAP = right-sided heart catheterization–measured mean pulmonary arterial pressure, mRAP = mean right atrial 
pressure, PAWP = pulmonary artery wedge pressure, PH = pulmonary hypertension, PVRI = pulmonary vascular resistance index, RHC = 
right-sided heart catheterization, SvO
2
 = mixed venous oxygen saturation, TLCO = transfer factor for carbon monoxide, WHO = World 
Health Organization.
* here were 52 patients without PH and 218 with PH.
† here were 45 patients without PH and 258 with PH.
‡ Data are numbers of patients.
Table 2: Diagnostic Performance of Models 1 and 2
Parameter Model 1 Model 2
Correlation with RHC-measured mPAP 0.80 (0.75, 0.84) 0.80 (0.76, 0.85)
ICC with mPAP 0.78 (0.73, 0.83) 0.79 (0.73, 0.83)
Sensitivity (%) 93 (89, 96) 92 (88, 95)
Speciicity (%) 79 (65, 89) 59 (43, 74)
Positive predictive value (%) 96 (93, 98) 94 (90, 96)
Negative predictive value (%) 67 (53, 78) 51 (37, 65)
Positive likelihood ratio 4.4 2.2
Negative likelihood ratio 0.09 0.14
AUC 0.95 (0.93, 0.98) 0.93 (0.90, 0.96)
Interobserver reproducibility 0.94 (0.81, 0.98) 0.88 (0.64, 0.96)
Note.—Numbers in parentheses are 95% conidence intervals. AUC = area under the receiver 
operating characteristic curve, ICC = intraclass correlation coeicient, mPAP = mean pulmonary 
arterial pressure, RHC = right-sided heart catheterization.
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58%, 83%). Cardiac MRI mPAP model 2 had a sensitivity of 
94% (95% CI: 91%, 97%), speciicity of 51% (95% CI: 37%, 
65%), positive predictive value of 92% (95% CI: 88%, 94%), 
and negative predictive value 61% (95% CI: 45%, 75%).
Interobserver reproducibility analysis showed an intraclass 
correlation coeicient of 0.94 (95% CI: 0.81, 0.98) for car-
diac MRI mPAP model 1 and 0.88 (95% CI: 0.64, 0.96) for 
cardiac MRI mPAP model 2.
Discussion
Interventricular septal angle, ventricular mass index, and black 
blood slow low score were independent cardiac MRI predic-
tors of mean pulmonary arterial pressure (mPAP), with addi-
tive value for the diagnosis of pulmonary hypertension (PH). 
We have derived a linear regression model, a composite of these 
three measurements (in 300 patients), and have shown high 
diagnostic accuracy in a large validation cohort (a further 303 
patients), identifying a threshold of at least 25 mm Hg as the 
optimal threshold, equivalent to that with RHC.
Our proposed cardiac MRI mPAP 1 (right venticle and black 
blood) model comprises measurement of displacement of the in-
terventricular septum (a marker of the pressure and volume dif-
ferential between the left and right ventricle), remodeling of the 
right ventricle (ventricular mass index), and slow or turbulent low 
in the pulmonary artery at black blood imaging. hese measure-
ments are easily acquired from standard cardiac MRI sequences, 
require little postprocessing time, and are reproducible (20). Black 
blood pulmonary arterial low score is a reproducible marker of 
outcome in pulmonary arterial hypertension (21). In healthy 
correlation coeicient of 0.79 (95% CI: 0.73, 0.83). Figure 4 
shows the scatterplots and Bland-Altman plots for cardiac MRI 
mPAP models 1 and 2.
Diagnostic accuracy.—Cardiac MRI mPAP model 1 
showed high diagnostic accuracy (area under the ROC curve 
= 0.95; 95% CI: 0.93, 0.98). he threshold of at least 25 mm 
Hg had a sensitivity of 93% (95% CI: 89%, 96%), speciicity 
of 79% (95% CI: 65%, 89%), positive predictive value of 
96% (95% CI: 93%, 98%), negative predictive value of 67% 
(95% CI: 53%, 78%), positive likelihood ratio of 4.4, and 
negative likelihood ratio of 0.09.
Cardiac MRI mPAP model 2 (25 mm Hg) had a sensitiv-
ity of 92% (95% CI: 88%, 95%), speciicity of 59% (95% CI: 
43%, 74%), positive predictive value of 94% (95% CI: 90%, 
96%), negative predictive value of 51% (95% CI: 37%, 65%), 
positive likelihood ratio of 2.2, and negative likelihood ratio 
of 0.14. ROC curve analysis of cardiac MRI mPAP model 2 
showed an area under the ROC curve of 0.93 (95% CI: 0.90, 
0.96). here was no signiicant diference in the area under the 
ROC curve between these models (P = .24). Figure 5 shows the 
ROC curves for both models, and Table 2 provides a summary 
of the diagnostic performance of both models.
After exclusion of all patients with PH due to left-sided heart 
disease, in addition to exclusion of patients with a left atrial vol-
ume index of less than 41 mL, cardiac MRI mPAP model 1 had 
a sensitivity of 94% (95% CI: 91%, 97%), speciicity of 79% 
(95% CI: 65%, 89%), positive predictive value of 96% (95% 
CI: 93%, 98%), and negative predictive value of 72% (95% CI: 
Figure 4: A, B, Scatterplots show correlation of, A, cardiac MRI (CMR) mean pulmonary arterial pressure (mPAP) model 1 
(the model based on metrics from right ventricle and slow flow at black blood imaging) and, B, cardiac MRI mPAP model 2 
(the model based on metrics of the pulmonary artery and right ventricle) with right-sided heart catheterization–measured mPAP 
in validation cohort. C, D, Corresponding Bland-Altman plots. Dotted line shows bias and dashed lines show 95% levels of 
agreement.
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of patients with PH due to left-sided heart disease by using car-
diac MRI metrics such as transmitral low and left atrial and 
ventricular illing.
Our study has some limitations, including its single-center, 
retrospective design. To further assess the validity of our models, 
analysis of a further cohort of patients suspected of having PH is 
required at a diferent center. In addition, it is necessary to validate 
the models in a cohort with a relatively lower proportion of pa-
tients with PH. he tertiary referral center population potentially 
limits its applicability in the wider clinical setting. Black blood 
imaging may not be available in some centers, or sequence param-
eters may difer between centers. In these instances, cardiac MRI 
mPAP model 2 (right ventricle pulmonary artery) may be used 
based on the interventricular septal angle, ventricular mass index, 
diastolic pulmonary arterial size, and pulmonary arterial relative 
area change. he limits of agreement of cardiac MRI models are 
insuicient for accurate estimation of an individual mPAP value. 
However, diagnostic accuracy is high as a diagnostic test at the 
threshold of 25 mm Hg.
In conclusion, cardiac MRI has high diagnostic accuracy 
in a cohort of incident patients referred to a tertiary referral 
center with suspected pulmonary hypertension (PH). A re-
producible model comprising simple and easy-to-obtain met-
rics (interventricular septal angle, ventricular mass index, and 
black blood score) can enable the identiication of patients 
with PH with high accuracy. his model may improve the de-
tection rates of PH and enhance the noninvasive assessment 
of patients with this severe disease.
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individuals, the protons in the pulmonary artery that are excited 
are replaced by nonexcited protons from outside the ield of view. 
In patients with PH, the excited protons within the pulmonary 
artery remain, returning signal. his is likely to be a composite 
of slow low and vortical or turbulent low within the pulmonary 
artery. he increasing use of four-dimensional phase-contrast low 
imaging will likely allow this metric within the model to be im-
proved upon (22–24). he parameters of black blood imaging 
that are susceptible to low artifacts (section thickness, inversion 
time, echo time, echo train length, and cardiac triggering point) 
were kept the same between patients and could be easily adopted 
for standardized use in diferent centers.
Previous studies have shown that the measurement of septal 
deviation has diagnostic value in suspected PH (25); in addi-
tion, it has been shown previously that the addition of ventricu-
lar mass index to a measure of septal angle increased diagnostic 
accuracy (15). he current larger study further validates these 
observations and identiies that the addition of a measurement 
from the pulmonary vasculature increases diagnostic accuracy 
(ie, black blood slow low score or pulmonary artery size in di-
astole). Computational models of pulmonary arterial low have 
also been assessed for the diagnosis of PH (26). Further work to 
integrate such physiologic models would be of value.
In patients with PH due to left-sided heart disease, treatment 
is aimed at the underlying cause (often left ventricular diastolic 
dysfunction) and not at the pulmonary vasculature. As such, 
current guidelines recommend that patients suspected of having 
PH but who have left-sided heart disease and no features of se-
vere PH should not be referred to specialist centers (2). We have 
considered this recommendation in our patient selection, using 
cardiac MRI–derived left atrial volume index (27) (41 mL/m2) 
as a cardiac MRI marker for the presence of left-sided heart dis-
ease (11). Further work is required to improve the identiication 
Figure 5: Receiver operating characteristics (ROC) curve for 
cardiac MRI mean pulmonary arterial pressure (mPAP) models 
1 and 2. There is no significant difference between the two 
curves (P = .24). AUC = area under the ROC curve.
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